Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levopropranolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 7/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 6/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.97 |
| ▸ | NR2E1 | Q9Y466 | 5/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propranolol SCHEMBL9064508 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Propranolol SCHEMBL29349844 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Dexpropranolol SCHEMBL610656 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Propranolol SCHEMBL17838091 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Propranolol SCHEMBL41688 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Levopropranolol SCHEMBL41689 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Propranolol SCHEMBL1553064 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Dexpropranolol SCHEMBL30309315 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Propranolol SCHEMBL9183224 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 | |
| Propranolol SCHEMBL7397696 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1ADRB3SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137707-A1 | METHODS OF MODULATING ATXN2 EXPRESSION | UNIV OF UTAH RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | US | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| CN-120091810-A | Methods and highly bioavailable permeable compounds for treating viral diseases | 基里尔·迪丹克 | 2025-06-03 | — | — | CN | disclosed |
| US-20250170114-A1 | METHODS OF TREATMENT USING T-TYPE CALCIUM CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-3793561-B1 | METHOTREXATE COMPOUNDS FOR USE IN TREATING HIV INFECTIONS | NAT CENTRE FOR CELL SCIENCE (IN) | 2025-03-26 | — | — | EP | disclosed |
| EP-4472633-A2 | METHODS OF TREATMENT USING T-TYPE CALCIUM CHANNEL MODULATORS | Praxis Precision Medicines, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118785905-A | Methods of treatment using T-type calcium channel modulators | 普拉西斯精密医药公司 | 2024-10-15 | — | — | CN | disclosed |
| US-12031977-B2 | Ex vivo system for determining multiple drug-drug transporter interactions and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-09 | — | — | US | disclosed |
| US-12023336-B2 | Antiviral drug compounds and composition thereof | NATIONAL CENTRE FOR CELL SCIENCE (IN) | 2024-07-02 | — | — | US | disclosed |
| WO-2023187599-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | DIDENKO KIRILL (MX) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023150703-A2 | METHODS OF TREATMENT USING T-TYPE CALCIUM CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137707-A1 | METHODS OF MODULATING ATXN2 EXPRESSION | ATXN2, ATXN2L, ATP6V1B2 | ADRB2 3797/4885ADRB1 4417/4885ADRB3 3589/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | ADRB2 3245/4885ADRB1 3582/4885ADRB3 4042/4885 |
| US-20250170114-A1 | METHODS OF TREATMENT USING T-TYPE CALCIUM CHANNEL MODULATORS | CACNA1H, CACNA1I, CACNA1G | ADRB2 827/4885ADRB1 622/4885ADRB3 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.